<DOC>
	<DOCNO>NCT00187031</DOCNO>
	<brief_summary>In spite overall success treat Wilms tumor , certain patient still poor clinical outcome . The sub-optimal outcome patient anaplastic histology recurrent Wilms tumor warrant identification new therapeutic agent . The objective trial estimate response rate two cycle intravenous topotecan child recurrent Wilms tumor favorable histology refractory standard curative therapy .</brief_summary>
	<brief_title>A Phase II Study Topotecan Children With Recurrent Wilms Tumor</brief_title>
	<detailed_description>Topotecan administer intravenously 30 minute daily 5 consecutive day 2 consecutive week , two-day rest give five-day treatment block . The topotecan dose start 1.8 mg/m2/dosage adjust attain target systemic exposure 80 plus minus 10 ng-hr/ml.each cycle consist 28 day subsequent cycle administer upon hematological recovery . Patients CR , PR , SD , continue receive total six cycle . Patients PD remove study . Secondary Objectives include : - To describe anti-tumor activity topotecan child recurrent Wilms tumor anaplastic histology . - To assess relation CYP3A4/5 genotype pharmacokinetics pharmacodynamics topotecan . - To assess relation ABCG2 genotype pharmacokinetics pharmacodynamics topotecan .</detailed_description>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Favorable histology Wilms tumor recur progressed primary treatment least one standard salvage treatment regimen OR anaplastic histology Wilms tumor recur progressed primary treatment Age &lt; 21 year age time study entry Adequate bone marrow function Adequate liver function Adequate renal function Adequate performance status Subject pregnant Subject lactate Renal tumor Wilms tumor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Wilms Tumor</keyword>
</DOC>